Alpha Cognition to Present at Spartan Capital Investor Conference, Highlighting Neurodegenerative Disease Treatments

Alpha Cognition Inc. (NASDAQ: ACOG) will present at the Spartan Capital Securities Second Annual Investor Conference on November 3, 2025, at the Marriott Marquis Hotel in New York City. This participation highlights the conference's mission to feature innovative companies positioned for long-term growth, particularly in the healthcare sector where Alpha Cognition focuses on developing treatments for neurodegenerative diseases. The company specializes in addressing conditions such as Alzheimer's Disease and Cognitive Impairment with mild Traumatic Brain Injury, areas where no approved treatment options currently exist.

Michael McFadden, CEO of Alpha Cognition, expressed enthusiasm about the opportunity to share the company's story with a distinguished audience of investors and peers. The conference provides a unique platform to highlight commercial and pipeline progress while connecting with new investors and strengthening relationships within the capital markets community. This visibility comes at a critical time for neurodegenerative disease research, as millions of patients worldwide await effective treatment options for conditions that currently have limited therapeutic interventions.

John D. Lowry, Founder and CEO of Spartan Capital Securities, noted the firm's delight in featuring Alpha Cognition at the annual investor conference. Spartan Capital has built its reputation on helping growth companies access appropriate investors and resources, with this conference serving as a powerful extension of that mission by bringing together high-quality issuers and serious capital providers. The event, organized in partnership with B2i Digital, will showcase more than 60 carefully selected companies across technology, healthcare, consumer, mining, precious metals, and other high-growth sectors, with over 500 institutional and high-net-worth investors expected to attend.

David Shapiro, CEO of B2i Digital, explained that Alpha Cognition was invited to share their perspective with attending investors as part of a broader commitment to connecting investors with diverse growth companies. This approach supports B2i Digital's core mission of combining digital marketing reach with face-to-face investor engagement. The conference will feature main-stage presentations, expert panels, curated one-on-one meetings, and extensive networking sessions, creating meaningful dialogue opportunities between growth companies and the investment community. For registration details, visit https://spartancapital.com.

The significance of Alpha Cognition's presentation extends beyond mere corporate visibility. As a commercial-stage biopharmaceutical company, their work addresses critical gaps in neurodegenerative disease treatment. The lack of approved options for conditions like cognitive impairment following mild traumatic brain injury represents a substantial unmet medical need. By presenting at this investor conference, Alpha Cognition gains access to capital markets that could accelerate development of these much-needed therapies, potentially benefiting patients suffering from these debilitating conditions worldwide.